{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122778","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.642757+00:00","generated_at":"2026-05-30T03:43:47.037188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1","bullets":["Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.","CLN-978 (SLE) IND cleared in US and Australia; Phase 1 starts; initial data expected Q4 2025.","Zipalertinib pivotal Phase 2b enrollment completed ahead of schedule; results mid-2025.","CLN-619 expansion data in endometrial/cervical cancers expected Q2 2025; patent issued to 2041.","R&D expense $35.5M, G&A $13.3M; both increased YoY from $33.8M and $11.0M respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122778","json":"https://secwatch.observer/filing/0000950170-24-122778.json","markdown":"https://secwatch.observer/filing/0000950170-24-122778.md","text":"https://secwatch.observer/filing/0000950170-24-122778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024122778/0000950170-24-122778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024122778/cgem-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:43:47.037188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}